Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

8.3%

2 terminated/withdrawn out of 24 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

8 recruiting

Enrollment Performance

Analytics

Early Phase 1
14(58.3%)
Phase 1
10(41.7%)
24Total
Early Phase 1(14)
Phase 1(10)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (24)

Showing 20 of 24 trials
NCT07249879Phase 1Recruiting

This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.

Role: collaborator

NCT07250269Phase 1Recruiting

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Role: lead

NCT06530849Phase 1Recruiting

A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

Role: lead

NCT06235229Phase 1Recruiting

A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

Role: lead

NCT07086404Early Phase 1Recruiting

GC012F Injection in Refractory Idiopathic Inflammatory Myopathy

Role: collaborator

NCT07058298Early Phase 1Recruiting

GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)

Role: collaborator

NCT07072884Early Phase 1Not Yet Recruiting

GC012F in Patients With Autoimmune Diseases

Role: collaborator

NCT06419166Early Phase 1Withdrawn

An Exploratory Clinical Study of GC012F Injection for Refractory gMG

Role: collaborator

NCT06880354Phase 1Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Role: collaborator

NCT06110208Early Phase 1Terminated

Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML

Role: collaborator

NCT06759948Phase 1Not Yet Recruiting

An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis

Role: collaborator

NCT05840107Early Phase 1Recruiting

Study of FasT CAR-T GC012F Injection NDMM Patients

Role: collaborator

NCT05858684Early Phase 1Unknown

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

Role: collaborator

NCT05846347Phase 1Unknown

Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus

Role: collaborator

NCT05105867Early Phase 1Unknown

CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies

Role: collaborator

NCT04935580Phase 1Unknown

Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

Role: collaborator

NCT05412329Phase 1Unknown

Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma

Role: collaborator

NCT04617704Early Phase 1Unknown

BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma

Role: collaborator

NCT04264078Early Phase 1Unknown

Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

Role: collaborator

NCT04236011Early Phase 1Unknown

BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma

Role: collaborator